Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,895,377 papers from all fields of science
Search
Sign In
Create Free Account
dalantercept
A soluble fusion protein containing the extracellular domain of activin receptor-like kinase-1 (ALK1) fused to a human Fc domain (ALK1-Fc fusion…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
ACE-041
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ALK1/VEGF Combo Active in Advanced RCC
L. Lawrence
2017
Corpus ID: 182306788
An early study looking at the combination of the ALK1 inhibitor dalantercept plus axitinib showed clinical activity in patients…
Expand
2013
2013
Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.
M. Atkins
,
R. Bhatt
,
+11 authors
S. Pandya
2013
Corpus ID: 56816617
TPS4595 Background: The treatment of metastatic renal cell cancer (mRCC) with therapies targeting the vascular endothelial growth…
Expand
2013
2013
Abstract 5080: Inhibiting the ALK1/BMP9 signaling pathway with dalantercept as an antiangiogenic therapy.
M. Alimzhanov
,
N. Solban
,
+9 authors
R. Bhatt
2013
Corpus ID: 72250413